🚨 Stanley Druckenmiller has just announced the latest investment portfolio of Duquesne Family Office as of the end of Q1/2026 — and the current picture shows large capital flows focusing heavily on AI, semiconductors, biotech, and emerging markets.

The largest holding remains Natera ($NTRA) with over $576 million, indicating Druckenmiller continues to make big bets on the biotech and genetic testing sectors.
Following are Taiwan Semiconductor ($TSM), STMicroelectronics ($STM), Broadcom ($AVGO), Arm Holdings ($ARM), Micron ($MU), and Intel ($INTC) — a clear signal that he remains extremely bullish on the AI cycle and global chip demand.
Besides technology, Druckenmiller also boosts positions in emerging markets such as Brazil ETF ($EWZ), Argentina ETF ($ARGT), YPF ($YPF), and Sea Limited ($SE).
This shows he is seeking growth in economies benefiting from the commodity cycle and international capital flows.
This portfolio also has a significant allocation to biotech with names like Insmed ($INSM), Revolution Medicines ($RVMD), Xenon Pharmaceuticals ($XENE), Olema Pharmaceuticals ($OLMA), Belite Bio ($BLTE), and ADMA Biologics ($ADMA).
This sector is highly volatile but has enormous growth potential if clinical trials succeed.
Additionally, Druckenmiller is betting on commodities and industry through Alcoa ($AA), Southern Copper ($SCCO), Cleveland-Cliffs ($CLF), Linde ($LIN), and iShares GSCI Commodity ETF ($GSG).
This Q1 portfolio reflects Druckenmiller’s familiar strategy: focusing on the biggest macro trends — AI, energy, commodities, and biotech innovation — rather than defensive investments.